MenaQ7® Crystals First Natural Vitamin K2 Launched in a Medical Food

OSLO, NORWAY - NattoPharma announces today the introduction of MenaQ7 Crystals in a prescription medical food called Fosteum PLUS® from Primus Pharmaceuticals.  This is the first medical food product to incorporate vitamin K2, targeting bone health while protecting cardiovascular health.  This represents an exclusive license for the bone-health category in medical foods.

Frode Marc Bohan, Chairman of NattoPharma ASA, says, "Medical food is a unique and exciting category providing therapeutic benefits under a physician’s care. The incorporation of MenaQ7 Crystals in Primus Pharmaceuticals’ Fosteum PLUS demonstrates that NattoPharma has met recognized scientific principles and entered the prescription, therapeutic drug medical market with MenaQ7. The product was launched in US October 2013 and is now offered directly to US-physicians by Primus. This represents a milestone in our ongoing pharmaceutical efforts."

Medical foods in the U.S. are specially formulated and intended for dietary management to meet distinctive nutritional requirements of a specific disease or condition that cannot be managed by a normal diet. Defined in the FDA Orphan Drug Act, medical foods are regulated and must be substantiated by recognized scientific principles, and are utilized under physician supervision. Fosteum PLUS is for the clinical dietary management of the metabolic processes associated with osteopenia and osteoporosis with MenaQ7 vitamin K2 for improved bone results and cardiac safety. Fosteum Plus can only be used with a physician’s prescription.

"Primus Pharmaceuticals is the market leader in manufacturing prescription metabolic products, and is an innovator in providing safe, therapeutic medical food options for physicians and their patients," says Eric Anderson, Global Vice President of marketing for NattoPharma. "Fosteum PLUS represents a ground-breaking development for bone health, as the inclusion of ultra-high purity; patented MenaQ7 is based on the unique three-year study, published in Osteoporosis International, which demonstrates MenaQ7’s clear preservation of bone constitution and strength in menopausal women."

MenaQ7’s clear preservation of bone constitution and strength in menopausal women."

# # #

About Primus Pharmaceuticals

Primus is the first specialty pharmaceutical company to focus on prescription metabolic products which improve patient quality of life without compromising safety. Primus develops branded prescription drugs and prescription medical foods that are patented and effective in chronic or recurring diseases. The Company's unique approach is to develop safe prescription products formulated to restore metabolic processes at the disease source rather than focusing on symptoms. Primus promotes to targeted physician specialists and extends its sales coverage and clinical capabilities through strategic partnerships. Primus is privately held, based in Scottsdale, AZ, and can be contacted at www.primusrx.com. Primus’ brands include: Limbrel® (flavocoxid), Fosteum® PLUS (calcium compounds/phosphate/genisteinaglycone/citrated zinc bisglycinate/trans-menaquinone-7/cholecalciferol), Vasculera (diosmiplex), and Alcortin® A (iodoquinol/hydrocortisone acetate/aloe polysaccharide).

About NattoPharma and MenaQ7®

As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator of Vitamin K2 menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in an exclusive research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Europe

Dr. Hogne Vik

CEO, NattoPharma

Cell phone: +47 97 53 53 26

E-mail: Hogne.Vik@NattoPharma.com

Rest of World

Eric Anderson

SR. VP Global Sales & Marketing

Phone: +1 609 454 2992

Email: Eric.Anderson@NattoPharma.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.